Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma. Fourteen patients were enrolled in the study, eleven of whom qualified to receive ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Shah, J J, Feng, L, Thomas, S K, Berkova, Z, Weber, D M, Wang, M, Qazilbash, M H, Champlin, R E, Mendoza, T R, Cleeland, C, Orlowski, R Z
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771967/
https://ncbi.nlm.nih.gov/pubmed/26871714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados